Analytical Data
-
基因名
Carboxypeptidase A1/CPA1
- Application
-
种属
Rat
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
P00731
-
表达区间
Thr205~Tyr419
-
分子量
28kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Carboxypeptidase A1 (CPA1) is a crucial enzyme involved in the digestion of proteins in the pancreas. It primarily functions as an exopeptidase, cleaving amino acids from the carboxyl terminal of peptides. Research into CPA1 has gained significance due to its implications in various physiological processes and potential roles in diseases, including pancreatitis and pancreatic cancer. Furthermore, CPA1 is of interest in biotechnology and pharmaceutical applications, where it can be used in protein engineering and as a therapeutic target. The recombinant form of CPA1 allows for extensive studies on its structural and functional characteristics, offering insights into its enzymatic mechanisms and interactions with substrates. The production of recombinant CPA1 not only facilitates a better understanding of its biological functions but also aids in exploring its potential as a biomarker for disease diagnosis and prognosis. Additionally, studies on CPA1 provide a platform for developing inhibitors or modulators that can be beneficial in managing conditions related to exocrine pancreatic dysfunction. As such, research on CPA1 recombinant protein continues to be a dynamic field with broad implications in health and disease management.
